|Day Low/High||0.00 / 0.00|
|52 Wk Low/High||40.58 / 69.53|
Six charts showing signs of smart money footprints.
The biotech company plans to commercialize its treatment for AL amyloidosis, a disease that causes protein to build up in the blood.
Karyopharm Therapeutics falls 18%; Lexicon rises on drug approval.
Data Previously Presented in 2015 at 19th International Congress of Parkinson's Disease and Movement Disorders